Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 105
- Registration Number
- NCT03371355
- Locations
- 🇺🇸
Clinical Sites, Chandler, Arizona, United States
🇨🇦Clinical Site, Montréal, Quebec, Canada
Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT03360747
- Locations
- 🇨🇦
Investigative Site, Montréal, Quebec, Canada
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 286
- Registration Number
- NCT03070782
- Locations
- 🇳🇱
Clinical Site, Amsterdam, Netherlands
The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-01-18
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 68
- Registration Number
- NCT02658175
- Locations
- 🇬🇧
IONIS Investigative Site, Manchester, United Kingdom
The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT02527343
- Locations
- 🇷🇺
IONIS Investigative Site, Moscow, Russian Federation
© Copyright 2024. All Rights Reserved by MedPath